Metabolic syndrome (MS) represents a cluster of cardiovascular risk factors that includes hypertriglyceridemia. Although low-density lipoprotein (LDL) cholesterol is the critical therapeutic target in patients with coronary artery disease, LDL cannot be calculated in those with excessive hypertriglyceridemia. Non-high-density lipoprotein (HDL) does not require LDL for calculation and may be an alternative therapeutic target in MS. The purpose of this study was to determine non-HDL cholesterol in relation to other lipid components and comorbidities in MS patients.
Methods
A cross-sectional chart review on 928 public hospital patients was performed.
Results
Metabolic syndrome was present in 53% of all patients. Among those with MS, 87% had triglyceride level of greater than 150 mg/dL, 85% had low HDL, 71% had LDL of greater than 100 mg/dL, and 74% had non-HDL of greater than 130 mg/dL. The level of non-HDL cholesterol, but not total cholesterol or LDL cholesterol, was significantly higher (P < 0.05) and less at goal (P < 0.0001) in patients with MS. Diagnoses of coronary artery disease, hypertension, obesity, dyslipidemia, and diabetes were significantly more prevalent in MS patients (P < 0.0001).
Conclusion
Compared with those without MS, non-HDL level was significantly higher and undertargeted in patients with MS, in parallel with significantly higher prevalence of comorbidities.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497.
2.
GrundySM, BrewerHBJr, CleemanJI, . Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433–438.
3.
FordES, GilesWH, MokdadAH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27(10):2444–2449.
4.
KulloIJ, CassidyAE, PeyserPA, . Association between metabolic syndrome and subclinical coronary atherosclerosis in asymptomatic adults. Am J Cardiol. 2004;94(12):1554–1558.
5.
McNeillAM, RosamondWD, GirmanCJ, . Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol. 2004;94(10):1249–1254.
6.
HuFB, StampferMJ, HaffnerSM, . Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25(7):1129–1134.
7.
GamiAS, WittBJ, HowardDE, . Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49(4):403–414.
8.
JacobsDRJr, MebaneIL, BangdiwalaSI, . High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1990;131(1):32–47.
9.
GordonT, CastelliWP, HjortlandMC, . High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707–714.
10.
LaRosaJC, HeJ,VupputuriS. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.JAMA. 1999;282(24):2340–2346.
11.
BaigentC, KeechA, KearneyPM, . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
12.
GrundySM, CleemanJI, MerzCN, . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239.
13.
FriedewaldWT, LevyRI, FredricksonDS.Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
14.
GalanisDJ, SobalJ, McGarveyST, . Ten-year changes in the obesity, abdominal adiposity, and serum lipoprotein cholesterol measures of Western Samoan men. J Clin Epidemiol. 1995;48(12):1485–1493.
15.
ChanDC, WattsGF, BarrettPH, . Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem. 2002;48(2):278–283.
16.
PedersenTR, OlssonAG, FaergemanO, . Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97(15):1453–1460.
17.
BittnerV, HardisonR, KelseySF, . Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 2002;106(20):2537–2542.
18.
FrostPH, DavisBR, BurlandoAJ, . Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation. 1996;94(10):2381–2388.
19.
CuiY, BlumenthalRS, FlawsJA, . Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161(11):1413–1419.
20.
FarwellWR, SessoHD, BuringJE, . Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol as a risk factor for a first nonfatal myocardial infarction. Am J Cardiol. 2005;96(8):1129–1134.
21.
ShaiI, RimmEB, HankinsonSE, . Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation. 2004;110(18):2824–2830.
22.
RidkerPM, RifaiN, CookNR, . Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294(3):326–333.
23.
LuW, ResnickHE, JablonskiKA, . Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care. 2003;26(1):16–23.
24.
JiangR, SchulzeMB, LiT, . Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care. 2004;27(8):1991–1997.
25.
LehtoS, RonnemaaT, HaffnerSM, . Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 1997;46(8):1354–1359.
WagnerAM, PerezA, ZapicoE, . Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. Diabetes Care. 2003;26(7):2048–2051.
28.
SattarN, WilliamsK, SnidermanAD, . Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation. 2004;110(17):2687–2693.
29.
GrundySM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 2002;106(20):2526–2529.
30.
PyoralaK, BallantyneCM, GumbinerB, . Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 2004;27(7):1735–1740.
31.
AthyrosVG, MikhailidisDP, PapageorgiouAA, . Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin. 2004;20(9):1385–1392.
32.
DavidsonMH, MakiKC, PearsonTA, . Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96(4):556–563.
33.
BallantyneCM, AndrewsTC, HsiaJA, . Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 2001;88(3):265–269.
34.
JacobsonTA, CaseCC, RobertsS, . Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes Obes Metab. 2004;6(5):353–362.
